Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial

Lancet

Volumn 370, Issue 9602, 2007, Pages 1847-1853

  Tauber, E ^e   Kollaritsch, H ^a   Korinek, M ^a   Rendi Wagner, P ^a   Jilma, B ^b   Firbas, C ^b   Schranz, S ^b   Jong, E ^c   Klingler, A ^d   Dewasthaly, S ^e   Klade, CS ^e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF WASHINGTON   (United States)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e INTERCELL AG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

JAPANESE ENCEPHALITIS TEST VACCINE; JAPANESE ENCEPHALITIS VACCINE; PLACEBO; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; AUSTRIA; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIDEMIC ENCEPHALITIS; FATIGUE; FEMALE; FLU LIKE SYNDROME; GERMANY; HEADACHE; HEART INFARCTION; HUMAN; IMMUNOGENICITY; JAPANESE ENCEPHALITIS VIRUS; MALE; MULTICENTER STUDY; MYALGIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SEROCONVERSION; SERODIAGNOSIS; SINGLE BLIND PROCEDURE; UNITED STATES; VERO CELL;

EID: 36549069631     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61780-2     Document Type: Article

References (33)

1. Solomon T. Control of Japanese encephalitis-within our grasp?. N Engl J Med 355 (2006) 869-871
2. Solomon T., and Whitley R. Arthropod-borne viral encephalitides. In: Scheld M., Whitley R., and Marra C. (Eds). Infections of the central nervous system. 2nd edn. (2004), Lippincott Williams and Wilkins, Philidelphia, PA
3. Parida M., Dash P., Tripathi N., et al. Japanese encephalitis outbreak, India, 2005. Emerg Infect Dis 12 (2006) 1427-1430
4. 14-14-2): a case-control study. Lancet 347 (1996) 1583-1586
5. Bista M., Banerjee M., Shin S., et al. Efficacy of single-dose SA14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 358 (2001) 791-795
6. 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet 366 (2005) 1375-1378
7. Tsai T. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine 18 suppl 2 (2000) 1-25
8. Hoke C., Nisalak A., Sangawhipa N., et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 319 (1988) 608-614
9. Marfin A., Eidex R., Kozarsky P., and Cetron M. Yellow fever and Japanese encephalitis vaccines: indications and complications. Infect Dis Clin North Am 19 (2005) 151-168
10. WHO. Wkly Epidemiol Record 80 (2005) 241-248. http://www.who.int/wer/2005/wer8028.pdf (accessed Sept 12, 2007).
11. Monath T., Guirakhoo F., Nichols R., et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 188 (2003) 1213-1230
12. Hombach J., Barrett A., Cardosa M., et al. Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. Vaccine 23 (2005) 2689-2695
13. Hammon W., and Sather G. Passive immunity for arbovirus infection. I Artificially induced prophylaxis in man and mouse for Japanese (B) encephalitis. Am J Trop Med Hyg 22 (1973) 524-534
14. Lyons A., Kanesathasan N., Kuschner R., et al. A phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 25 (2007) 3445-3453
15. Monnet F. Behavioural disturbances following Japanese B encephalitis. Eur Psychiatry 18 (2003) 269-273
16. Ostlund M., Kan B., Karlsson M., and Vene S. Japanese encephalitis in a swedish tourist after travelling to Java and Bali. Scand J Infect Dis 36 (2004) 512-513
17. Shlim D., and Solomon T. Japanese encephalitis vaccine for travelers: exploring the limits of risk. Clin Infect Dis 35 (2002) 183-188
18. Ahmad K. Fury after children's adverse reaction to Japanese encephalitis vaccine. Lancet 360 (2002) 395
19. Plesner A., Arlien-Soborg P., and Herning M. Neurological complications and Japanese encephalitis vaccination. Lancet 348 (1996) 202-203
20. Ruff T., Eisen D., Fuller A., and Kass R. Adverse reactions to Japanese encephalitis vaccine. Lancet 338 (1991) 881-882
21. Andersen M., and Ronne T. Side-effects with Japanese encephalitis vaccine. Lancet 337 (1991) 1044
22. WHO. Wkly Epidemiol Record 82 (2007) 17-24. http://www.who.int/wer/2007/wer8203.pdf (accessed Sept 12, 2007).
23. Seligman S., and Gould E. Live flavivirus vaccines: reasons for caution. Lancet 363 (2004) 2073-2075
24. Hombach J., Kurane I., and Wood D. Arguments for live flavivirus vaccines. Lancet 364 (2004) 498-499
25. 14-14-2): results of a randomized trial with 26 239 subjects. J Infect Dis 176 (1997) 1366-1369
26. Markoff L. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine 18 suppl 2 (2000) 26-32
27. Hombach J., Solomon T., Kurane I., Jacobson J., and Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 23 (2005) 5205-5211
28. Oya A. Japanese encephalitis vaccine. Acta Paediatr Jpn 30 (1988) 175-184
29. Chen R., Markowitz L., Albrecht P., et al. Measles antibody: reevaluation of protective titers. J Infect Dis 162 (1990) 1036-1042
30. Robinson H., Russell M., and Csokonay W. Japanese encephalitis vaccine and adverse effects among travellers. Can Dis Wkly Rep 17 (1991) 173-174
31. Arness M., Eckart R., Love S., et al. Myopericarditis following smallpox vaccination. Am J Epidemiol 160 (2004) 642-651
32. Ghoshal A., Das S., Ghosh S., et al. Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis. Glia 55 (2007) 483-496
33. CDC. Inactivated Japanese encephalitis virus vaccine recommendations of the advisory committee on immunization practices (ACIP). http://www.cdc.gov/mmwr/preview/mmwrhtml/00020599.htm (accessed Sept 12, 2007).